Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 14/20 | 0.73 |
| ▸ | LPL | P06858 | 13/20 | 0.73 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | TDO2 | P48775 | 1/20 | 0.40 |
| ▸ | SNCA | P37840 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26549551 | 0.95 | LIPG (0.71) | LIPGLPLIDO1TDO2SNCA | |
| SCHEMBL1769950 | 0.87 | LPL (0.61) | LIPGLPLIDO1TDO2SNCA | |
| SCHEMBL24377051 | 0.86 | LIPG (0.79) | LIPGLPLSNCACA1CA2 | |
| SCHEMBL29587465 | 0.86 | LIPG (0.79) | LIPGLPLSNCACA1CA2 | |
| SCHEMBL10018882 | 0.86 | LIPG (0.79) | LIPGLPLSNCACA1CA2 | |
| SCHEMBL24377031 | 0.86 | LIPG (0.79) | LIPGLPLSNCACA1CA2 | |
| SCHEMBL24377088 | 0.86 | LIPG (0.79) | LIPGLPLSNCACA1CA2 | |
| SCHEMBL792244 | 0.85 | LIPG (1.00) | LIPGLPLSNCACA1CA2 | |
| SCHEMBL431713 | 0.84 | LIPG (0.88) | LIPGLPLSNCACA1CA2 | |
| SCHEMBL31139946 | 0.84 | LIPG (0.88) | LIPGLPLSNCACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230337527-A1 | ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME | LAPTO CO., LTD. (KR) | 2023-10-19 | — | — | US | disclosed |
| US-20230337527-A1 | ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME | LAPTO CO., LTD. (KR) | 2023-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230337527-A1 | ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME | AOC1, ODC1, PIEZO1 | LIPG 2567/4885LPL 2737/4885IDO1 2053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.